BioSyent, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA0906901081
CAD
15.50
0.3 (1.97%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

2.6 k

Shareholding (Mar 2025)

FII

0.00%

Held by 1 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

High Management Efficiency with a high ROE of 18.15%

 
2

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 7.50

 
3

With a growth in Net Profit of 32.91%, the company declared Very Positive results in Sep 25

4

With ROE of 21.64%, it has a fair valuation with a 4.45 Price to Book Value

5

Consistent Returns over the last 3 years

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CAD 177 Million (Small Cap)

stock-summary
P/E

21.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.58

stock-summary
Return on Equity

21.64%

stock-summary
Price to Book

4.45

Revenue and Profits:
Net Sales:
12 Million
(Quarterly Results - Sep 2025)
Net Profit:
3 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
26.53%
0%
26.53%
6 Months
29.17%
0%
29.17%
1 Year
37.78%
0%
37.78%
2 Years
80.44%
0%
80.44%
3 Years
113.79%
0%
113.79%
4 Years
86.07%
0%
86.07%
5 Years
111.46%
0%
111.46%

BioSyent, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
13.72%
EBIT Growth (5y)
12.58%
EBIT to Interest (avg)
7.50
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.48
Sales to Capital Employed (avg)
0.96
Tax Ratio
25.74%
Dividend Payout Ratio
29.49%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
100.69%
ROE (avg)
18.15%

Valuation key factors

Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
4.45
EV to EBIT
14.22
EV to EBITDA
13.17
EV to Capital Employed
9.23
EV to Sales
3.66
PEG Ratio
0.91
Dividend Yield
NA
ROCE (Latest)
64.92%
ROE (Latest)
21.64%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 19.61% vs -7.27% in Jun 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 35.00% vs -13.04% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "12.20",
          "val2": "10.20",
          "chgp": "19.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "3.60",
          "val2": "2.80",
          "chgp": "28.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2.70",
          "val2": "2.00",
          "chgp": "35.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "278.90%",
          "val2": "252.10%",
          "chgp": "2.68%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 10.76% vs 13.26% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 12.31% vs 18.18% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "35.00",
          "val2": "31.60",
          "chgp": "10.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "9.20",
          "val2": "8.00",
          "chgp": "15.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "7.30",
          "val2": "6.50",
          "chgp": "12.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "246.50%",
          "val2": "238.50%",
          "chgp": "0.80%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQstock-summary

Sep'25
Jun'25
Change(%)
Net Sales
12.20
10.20
19.61%
Operating Profit (PBDIT) excl Other Income
3.60
2.80
28.57%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
2.70
2.00
35.00%
Operating Profit Margin (Excl OI)
278.90%
252.10%
2.68%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Sep 2025 is 19.61% vs -7.27% in Jun 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is 35.00% vs -13.04% in Jun 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
35.00
31.60
10.76%
Operating Profit (PBDIT) excl Other Income
9.20
8.00
15.00%
Interest
0.10
0.10
Exceptional Items
0.00
0.00
Consolidate Net Profit
7.30
6.50
12.31%
Operating Profit Margin (Excl OI)
246.50%
238.50%
0.80%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 10.76% vs 13.26% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 12.31% vs 18.18% in Dec 2023

stock-summaryCompany CV
About BioSyent, Inc. stock-summary
stock-summary
BioSyent, Inc.
Pharmaceuticals & Biotechnology
BioSyent Inc. is a specialty pharmaceutical company. The Company, through its subsidiary, BioSyent Pharma Inc., acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. It has four business units: the Community and Women's Health Unit, which commercializes pharmaceutical products focused on improving family and women's health; the Hospital Business Unit, which sells pharmaceutical products to hospitals and hospital specialists; the International Pharmaceutical Unit, and the Legacy Business. Its products include FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Aguettant System and Cysview. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. Cathejell is indicated for surface anesthesia and lubrication for various procedures. RepaGyn helps relieve dryness and promotes healing of the vaginal mucosa. It also manufactures and markets Protect-It, a non-toxic product.
Company Coordinates stock-summary
Company Details
170 Attwell Dr Suite 520 , ETOBICOKE ON : M9W 5Z5
stock-summary
Tel: 1 905 2060013
stock-summary
Registrar Details